FrancophonIA/ELRC3.0 huggingface dataset:
English: Oprymea 0.26 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/026 30 prolonged-release tablets: EU/1/08/469/027 90 prolonged-release tablets: EU/1/08/469/028 100 prolonged-release tablets: EU/1/08/469/029
Croatian: Oprymea 0,26 mg tablete s produljenim oslobađanjem 10 tableta s produljenim oslobađanjem: EU/1/08/469/026 30 tableta s produljenim oslobađanjem: EU/1/08/469/027 90 tableta s produljenim oslobađanjem: EU/1/08/469/028 100 tableta s produljenim oslobađanjem: EU/1/08/469/029
English: 0.52 mg: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots.
Croatian: 0,52 mg: Bijele ili gotovo bijele, okrugle (promjera 10 mm), blago bikonveksne tablete s utisnutom oznakom P2 na jednoj strani, s ukošenim rubovima i mogućim točkicama.
English: Oprymea 0.26 mg prolonged-release tablets Each prolonged-release tablet contains 0.26 mg pramipexole (as 0.375 mg pramipexole dihydrochloride monohydrate).
Croatian: Oprymea 0,26 mg tablete s produljenim oslobađanjem Jedna tableta s produljenim oslobađanjem sadrži 0,26 mg pramipeksola (u obliku 0,375 mg pramipeksoldiklorid hidrata).
English: Oprymea 0.7 mg tablets 20 tablets: EU/1/08/469/016 30 tablets: EU/1/08/469/017 60 tablets: EU/1/08/469/018 90 tablets: EU/1/08/469/019 100 tablets: EU/1/08/469/020
Croatian: Oprymea 0,7 mg tablete 20 tableta: EU/1/08/469/016 30 tableta: EU/1/08/469/017 60 tableta: EU/1/08/469/018 90 tableta: EU/1/08/469/019 100 tableta: EU/1/08/469/020
English: Oprymea 2.1 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/042 30 prolonged-release tablets: EU/1/08/469/043 90 prolonged-release tablets: EU/1/08/469/044 100 prolonged-release tablets: EU/1/08/469/045
Croatian: Oprymea 2,1 mg tablete s produljenim oslobađanjem 10 tableta s produljenim oslobađanjem: EU/1/08/469/042 30 tableta s produljenim oslobađanjem: EU/1/08/469/043 90 tableta s produljenim oslobađanjem: EU/1/08/469/044 100 tableta s produljenim oslobađanjem: EU/1/08/469/045
English: EU/1/08/469/016 [20 tablets] EU/1/08/469/017 [30 tablets] EU/1/08/469/018 [60 tablets] EU/1/08/469/019 [90 tablets] EU/1/08/469/020 [100 tablets]
Croatian: EU/1/08/469/016 [20 tableta] EU/1/08/469/017 [30 tableta] EU/1/08/469/018 [60 tableta] EU/1/08/469/019 [90 tableta] EU/1/08/469/020 [100 tableta]
English: Oprymea 1.57 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/038 30 prolonged-release tablets: EU/1/08/469/039 90 prolonged-release tablets: EU/1/08/469/040 100 prolonged-release tablets: EU/1/08/469/041
Croatian: Oprymea 1,57 mg tablete s produljenim oslobađanjem 10 tableta s produljenim oslobađanjem: EU/1/08/469/038 30 tableta s produljenim oslobađanjem: EU/1/08/469/039 90 tableta s produljenim oslobađanjem: EU/1/08/469/040 100 tableta s produljenim oslobađanjem: EU/1/08/469/041
English: EU/1/08/469/042 [10 prolonged-release tablets] EU/1/08/469/043 [30 prolonged-release tablets] EU/1/08/469/044 [90 prolonged-release tablets] EU/1/08/469/045 [100 prolonged-release tablets]
Croatian: EU/1/08/469/042 [10 tableta s produljenim oslobađanjem] EU/1/08/469/043 [30 tableta s produljenim oslobađanjem] EU/1/08/469/044 [90 tableta s produljenim oslobađanjem] EU/1/08/469/045 [100 tableta s produljenim oslobađanjem]
English: EU/1/08/469/001[20 tablets] EU/1/08/469/002 [30 tablets] EU/1/08/469/003 [60 tablets] EU/1/08/469/004 [90 tablets] EU/1/08/469/005 [100 tablets]
Croatian: EU/1/08/469/001 [20 tableta] EU/1/08/469/002 [30 tableta] EU/1/08/469/003 [60 tableta] EU/1/08/469/004 [90 tableta] EU/1/08/469/005 [100 tableta]
English: EU/1/08/469/021 [20 tablets] EU/1/08/469/022 [30 tablets] EU/1/08/469/023 [60 tablets] EU/1/08/469/024 [90 tablets] EU/1/08/469/025 [100 tablets]
Croatian: EU/1/08/469/021 [20 tableta] EU/1/08/469/022 [30 tableta] EU/1/08/469/023 [60 tableta] EU/1/08/469/024 [90 tableta] EU/1/08/469/025 [100 tableta]
English: Oprymea 2.1 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P4 on one side, with bevelled edges and possible spots.
Croatian: Oprymea 2,1 mg tablete s produljenim oslobađanjem su bijele ili gotovo bijele boje, okrugle (promjera 10 mm), blago bikonveksne tablete s utisnutom oznakom P4 na jednoj strani, s ukošenim rubovima i mogućim točkicama.
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P4 on one side, with bevelled edges and possible spots.
Croatian: Bijele ili gotovo bijele, okrugle (promjera 10 mm), blago bikonveksne tablete s utisnutom oznakom P4 na jednoj strani, s ukošenim rubovima i mogućim točkicama.
English: Dyskinesia
Croatian: Nepoznato
English: EU/1/08/469/026 [10 prolonged-release tablets] EU/1/08/469/027 [30 prolonged-release tablets] EU/1/08/469/028 [90 prolonged-release tablets] EU/1/08/469/029 [100 prolonged-release tablets]
Croatian: EU/1/08/469/026 [10 tableta s produljenim oslobađanjem] EU/1/08/469/027 [30 tableta s produljenim oslobađanjem] EU/1/08/469/028 [90 tableta s produljenim oslobađanjem] EU/1/08/469/029 [100 tableta s produljenim oslobađanjem]
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots.
Croatian: Bijele ili gotovo bijele, okrugle (promjera 10 mm), blago bikonveksne tablete s utisnutom oznakom P1 na jednoj strani, s ukošenim rubovima i mogućim točkicama.
English: Oprymea 1.57 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P12 on one side, with bevelled edges and possible spots.
Croatian: Oprymea 1,57 mg tablete s produljenim oslobađanjem su bijele ili gotovo bijele boje, okrugle (promjera 10 mm), blago bikonveksne tablete s utisnutom oznakom P12 na jednoj strani, s ukošenim rubovima i mogućim točkicama.
English: Oprymea 3.15 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/050 30 prolonged-release tablets: EU/1/08/469/051 90 prolonged-release tablets: EU/1/08/469/052 100 prolonged-release tablets: EU/1/08/469/053
Croatian: Oprymea 3,15 mg tablete s produljenim oslobađanjem 10 tableta s produljenim oslobađanjem: EU/1/08/469/050 30 tableta s produljenim oslobađanjem: EU/1/08/469/051 90 tableta s produljenim oslobađanjem: EU/1/08/469/052 100 tableta s produljenim oslobađanjem: EU/1/08/469/053
English: Oprymea 1.05 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/034 30 prolonged-release tablets: EU/1/08/469/035 90 prolonged-release tablets: EU/1/08/469/036 100 prolonged-release tablets: EU/1/08/469/037
Croatian: Oprymea 1,05 mg tablete s produljenim oslobađanjem 10 tableta s produljenim oslobađanjem: EU/1/08/469/034 30 tableta s produljenim oslobađanjem: EU/1/08/469/035 90 tableta s produljenim oslobađanjem: EU/1/08/469/036 100 tableta s produljenim oslobađanjem: EU/1/08/469/037
English: Oprymea 0.52 mg prolonged-release tablets Pramipexole
Croatian: Oprymea 0,52 mg tablete s produljenim oslobađanjem pramipeksol
English: Oprymea 1.57 mg prolonged-release tablets Pramipexole
Croatian: Oprymea 1,57 mg tablete s produljenim oslobađanjem pramipeksol
English: EU/1/08/469/034 [10 prolonged-release tablets] EU/1/08/469/035 [30 prolonged-release tablets] EU/1/08/469/036 [90 prolonged-release tablets] EU/1/08/469/037 [100 prolonged-release tablets]
Croatian: EU/1/08/469/034 [10 tableta s produljenim oslobađanjem] EU/1/08/469/035 [30 tableta s produljenim oslobađanjem] EU/1/08/469/036 [90 tableta s produljenim oslobađanjem] EU/1/08/469/037 [100 tableta s produljenim oslobađanjem]
English: Oprymea 0.52 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots.
Croatian: Oprymea 0,52 mg tablete s produljenim oslobađanjem su bijele ili gotovo bijele boje, okrugle (promjera 10 mm), blago bikonveksne tablete s utisnutom oznakom P2 na jednoj strani, s ukošenim rubovima i mogućim točkicama.
English: Oprymea 0.52 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/030 30 prolonged-release tablets: EU/1/08/469/031 90 prolonged-release tablets: EU/1/08/469/032 100 prolonged-release tablets: EU/1/08/469/033
Croatian: Oprymea 0,52 mg tablete s produljenim oslobađanjem 10 tableta s produljenim oslobađanjem: EU/1/08/469/030 30 tableta s produljenim oslobađanjem: EU/1/08/469/031 90 tableta s produljenim oslobađanjem: EU/1/08/469/032 100 tableta s produljenim oslobađanjem: EU/1/08/469/033
English: EU/1/08/469/006 [20 tablets] EU/1/08/469/007 [30 tablets] EU/1/08/469/008 [60 tablets] EU/1/08/469/009 [90 tablets] EU/1/08/469/010 [100 tablets]
Croatian: EU/1/08/469/006 [20 tableta] EU/1/08/469/007 [30 tableta] EU/1/08/469/008 [60 tableta] EU/1/08/469/009 [90 tableta] EU/1/08/469/010 [100 tableta]
English: Oprymea 1.05 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P3 on one side, with bevelled edges and possible spots.
Croatian: Oprymea 1,05 mg tablete s produljenim oslobađanjem su bijele ili gotovo bijele boje, okrugle (promjera 10 mm), blago bikonveksne tablete s utisnutom oznakom P3 na jednoj strani, s ukošenim rubovima i mogućim točkicama.
English: Oprymea 1.05 mg prolonged-release tablets Pramipexole
Croatian: Oprymea 1,05 mg tablete s produljenim oslobađanjem pramipeksol
English: EU/1/08/469/050 [10 prolonged-release tablets] EU/1/08/469/051 [30 prolonged-release tablets] EU/1/08/469/052 [90 prolonged-release tablets] EU/1/08/469/053 [100 prolonged-release tablets]
Croatian: EU/1/08/469/050 [10 tableta s produljenim oslobađanjem] EU/1/08/469/051 [30 tableta s produljenim oslobađanjem] EU/1/08/469/052 [90 tableta s produljenim oslobađanjem] EU/1/08/469/053 [100 tableta s produljenim oslobađanjem]
English: Pramipexole
Croatian: Antipsihotici
English: EU/1/08/469/030 [10 prolonged-release tablets] EU/1/08/469/031[30 prolonged-release tablets] EU/1/08/469/032[90 prolonged-release tablets] EU/1/08/469/033[100 prolonged-release tablets]
Croatian: EU/1/08/469/030 [10 tableta s produljenim oslobađanjem] EU/1/08/469/031 [30 tableta s produljenim oslobađanjem] EU/1/08/469/032 [90 tableta s produljenim oslobađanjem] EU/1/08/469/033 [100 tableta s produljenim oslobađanjem]
English: EU/1/08/469/046 [10 prolonged-release tablets] EU/1/08/469/047 [30 prolonged-release tablets] EU/1/08/469/048 [90 prolonged-release tablets] EU/1/08/469/049 [100 prolonged-release tablets]
Croatian: EU/1/08/469/046 [10 tableta s produljenim oslobađanjem] EU/1/08/469/047 [30 tableta s produljenim oslobađanjem] EU/1/08/469/048 [90 tableta s produljenim oslobađanjem] EU/1/08/469/049 [100 tableta s produljenim oslobađanjem]
English: EU/1/08/469/038 [10 prolonged-release tablets] EU/1/08/469/039 [30 prolonged-release tablets] EU/1/08/469/040 [90 prolonged-release tablets] EU/1/08/469/041 [100 prolonged-release tablets]
Croatian: EU/1/08/469/038 [10 tableta s produljenim oslobađanjem] EU/1/08/469/039 [30 tableta s produljenim oslobađanjem] EU/1/08/469/040 [90 tableta s produljenim oslobađanjem] EU/1/08/469/041 [100 tableta s produljenim oslobađanjem]
English: Oprymea 0.26 mg prolonged-release tablets Pramipexole
Croatian: Oprymea 0,26 mg tablete s produljenim oslobađanjem pramipeksol
English: If you have advanced Parkinson's disease and are also taking levodopa, you might develop dyskinesia during the uptitration of Oprymea - Dystonia (inability of keeping your body and neck straight and upright (axial dystonia)).
Croatian: Ako imate uznapredovalu Parkinsonovu bolest te također uzimate levodopu, može doći do razvoja diskinezije tijekom povećavanja doze lijeka Oprymea.
English: Maize starch
Croatian: uključujući i pramipeksol.
English: What Oprymea looks like and contents of the pack Oprymea 0.088 mg tablets are white, round, with bevelled edges and imprint "P6" on one side of the tablet.
Croatian: Oprymea 0,088 mg tablete su bijele, okrugle, ukošenih rubova, s utisnutom oznakom "P6" na jednoj strani tablete.
English: Oprymea 2.1 mg prolonged-release tablets Pramipexole
Croatian: Oprymea 2,1 mg tablete s produljenim oslobađanjem pramipeksol
English: Oprymea 0.26 mg Oprymea 0.52 mg Oprymea 1.05 mg prolonged-release tablets Pramipexole
Croatian: Oprymea 0,26 mg tablete s produljenim oslobađanjem Oprymea 0,52 mg tablete s produljenim oslobađanjem Oprymea 1,05 mg tablete s produljenim oslobađanjem pramipeksol
English: Eye disorders visual impairment including diplopia vision blurred visual acuity reduced
Croatian: Nepoznato diplopiju zamućeni vid smanjena oštrina vida
English: Pregelatinised maize starch Povidone K25
Croatian: 6.1 Popis pomoćnih tvari manitol kukuruzni škrob škrob, prethodno geliran povidon K25 silicijev dioksid, koloidni, bezvodni magnezijev stearat
English: Dose reduction/tapered discontinuation should be considered if such symptoms develop.
Croatian: Ako se pojave takvi simptomi treba razmisliti o sniženju doze/postupnom ukidanju lijeka.
English: What Oprymea looks like and contents of the pack Oprymea 0.26 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots.
Croatian: Oprymea 0,26 mg tablete s produljenim oslobađanjem su bijele ili gotovo bijele boje, okrugle (promjera 10 mm), blago bikonveksne tablete s utisnutom oznakom P1 na jednoj strani, s ukošenim rubovima i mogućim točkicama.
English: What measures are being taken to ensure the safe and effective use of Viread?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Viread?
English: Viread (tenofovir disoproxil)
Croatian: Viread (tenofovirdizoproksil)
English: Side effects reported with Viread are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Viread pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: As for all medicines, data on the use of Viread are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Viread kontinuirano se prate.
English: What are the risks associated with Viread?
Croatian: Koji su rizici povezani s lijekom Viread?
English: Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI).
Croatian: Tenofovir je nukleotidni inhibitor reverzne transkriptaze (NRTI).
English: Moreover, Viread may cause a reduction in bone density.
Croatian: Osim toga, Viread može prouzročiti smanjenje gustoće kostiju.
English: Further information on Viread can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/viread.
Croatian: Lijek Viread dobio je odobrenje za stavljanje u promet koje je na snazi u EU-u od 5. veljače 2002. Više informacija o lijeku Viread nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/viread.
English: The company that makes Viread will ensure that all doctors who are expected to prescribe or use Viread in children are provided with educational materials containing important safety information, particularly on the risks and precautions relating to kidney function and the bones.
Croatian: Tvrtka koja proizvodi lijek Viread osigurat će da svi liječnici za koje se očekuje da će propisivati ili primjenjivati lijek Viread u djece dobiju edukativne materijale s važnim informacijama o sigurnosti primjene, posebice o rizicima i mjerama opreza povezanima s funkcijom bubrega i kostima.
English: Viread does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Croatian: Lijekom Viread ne liječi se infekcija HIV-om ni AIDS, no njegovom primjenom može se odgoditi narušavanje imunosnog sustava i razvoj infekcija i bolesti povezanih s AIDS-om.
English: The figure for the combination treatment of Viread and emtricitabine was 88%.
Croatian: Uz kombiniranu terapiju lijekom Viread i emtricitabinom ta je vrijednost bila 88 %.
English: For the treatment of HIV, Viread was more effective than placebo (a dummy treatment) when added to existing treatment.
Croatian: U liječenju infekcije HIV-om lijek Viread bio je učinkovitiji od placeba (prividno liječenje) kada se dodao postojećoj terapiji.
English: What is Viread and what is it used for?
Croatian: Što je Viread i za što se primjenjuje?
English: An overview of Viread and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Viread i zašto je odobren u EU-u
English: The European Medicines Agency decided that Viread's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Viread nadmašuju s njim povezane rizike te da on može biti odobren za primjenu u Europskoj uniji.
English: Viread is used in combination with other HIV medicines.
Croatian: Viread se primjenjuje u kombinaciji s drugim lijekovima protiv HIV-a.
English: The dose may need to be reduced or the medicine given less often in patients who have moderately or severely reduced kidney function.
Croatian: Dozu će možda biti potrebno smanjiti odnosno lijek će možda trebati davati rjeđe u bolesnika s umjerenim ili ozbiljnim oštećenjem funkcije bubrega.
English: For patients who have taken medicines to treat HIV infection before, doctors should only prescribe Viread once they have looked at the antiviral medicines the patient has taken before or the likelihood that the virus will respond to antiviral medicines.
Croatian: U bolesnika koji su prethodno uzimali lijekove za liječenje infekcije HIV-om liječnici trebaju propisati lijek Viread tek nakon što su provjerili kojim je protuvirusnim lijekovima bolesnik prethodno liječen i vjerojatnost odgovora virusa na protuvirusne lijekove.
English: The most common side effects with Viread (seen in more than 1 patient in 10) are nausea (feeling sick), vomiting, diarrhoea, dizziness, hypophosphataemia (low levels of phosphate in the blood), rash and asthenia (weakness).
Croatian: Najčešće su nuspojave lijeka Viread (opažene u više od 1 na 10 bolesnika) mučnina, povraćanje, proljev, omaglica, hipofosfatemija (niska razina fosfata u krvi), osip i astenija (opća slabost).
English: In HIV infection, it blocks the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses.
Croatian: U slučaju infekcije HIV-om on onemogućuje djelovanje povratne transkriptaze, enzima kojeg stvara HIV i koji virusu omogućuje da zarazi stanice i stvori veći broj virusa.
English: In children and adolescents it is only used in patients who cannot be treated with other first-line nucleotide reverse transcriptase inhibitors (NRTI).
Croatian: U djece i adolescenata primjenjuje se samo u bolesnika koji se ne mogu liječiti drugim nukleotidnim inhibitorima reverzne transkriptaze (NRTI) kao lijekovima prve linije liječenja.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Viread have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Viread također se nalaze u sažetku opisa svojstava i u uputi o lijeku.
English: Viread, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Croatian: Kad se uzima u kombinaciji s drugim protuvirusnim lijekovima, Viread snižava koncentraciju HIV-a u krvi i održava je na niskoj razini.
English: Viread stops the virus making DNA and prevents it from multiplying and spreading.
Croatian: Viread zaustavlja virus u stvaranju DNK-a te sprječava njegovo razmnožavanje i širenje.
English: Why is Viread authorised in the EU?
Croatian: Zašto je lijek Viread odobren u EU-u?
English: The active substance in Viread, tenofovir disoproxil, is a ‘prodrug' that is converted into tenofovir in the body.
Croatian: Djelatna tvar lijeka Viread, tenofovirdizoproksil, je „prolijek” koji se u tijelu pretvara u tenofovir.
English: For more information about using Viread, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Viread pročitajte u uputi o lijeku odnosno obratite se liječniku ili ljekarniku.
English: A study carried out in 87 adolescents (12 to 18 years of age) investigated the effects of adding Viread to existing treatment.
Croatian: U ispitivanju provedenom na 87 adolescenata (u dobi od 12 do 18 godina) promatrani su učinci dodavanja lijeka Viread postojećoj terapiji.
English: Viread is a medicine used to treat patients aged 2 years and above infected with human immunodeficiency virus type 1 (HIV 1), a virus that causes acquired immune deficiency syndrome (AIDS).
Croatian: Viread je lijek koji se primjenjuje za liječenje bolesnika u dobi od dvije godine i starijih koji su zaraženi virusom humane imunodeficijencije tipa 1 (HIV-1), virusom koji uzrokuje sindrom stečene imunodeficijencije (AIDS).
English: In adults, it can also be used for those patients with liver damage whose liver is not working properly (decompensated liver disease) and those patients who do not respond to treatment with lamivudine (another medicine for hepatitis B infection).
Croatian: U odraslih se može primjenjivati i u bolesnika čija je jetra oštećena i ne funkcionira ispravno (dekompenzirana bolest jetre) kao i u bolesnika koji ne odgovaraju na liječenje lamivudinom (drugi lijek protiv hepatitisa B).
English: Viread is also used to treat chronic (long-term) hepatitis B virus infection in adults and children aged 2 years and above with liver damage whose liver is still working properly (compensated liver disease).
Croatian: Viread s primjenjuje i za liječenje kronične (dugotrajne) infekcije virusom hepatitisa B u odraslih i djece u dobi od dvije godine i starije čija je jetra oštećena, ali još uvijek ispravno funkcionira (kompenzirana bolest jetre).
English: Tenofovir also interferes with the action of an enzyme produced by the hepatitis B virus called DNA polymerase, which is involved in the formation of viral DNA.
Croatian: Tenofovir ometa i djelovanje enzima polimeraze DNK, kojeg proizvodi virus hepatitisa B i koji sudjeluje u stvaranju DNK virusa.
English: Overall, 70% of patients taking Viread or entecavir had a viral load below 400 copies/ml.
Croatian: Ukupno gledajući, 70 % bolesnika koji su primali lijek Viread ili entecavir imalo je virusno opterećenje manje od 400 kopija/ml.
English: For the treatment of hepatitis B, two studies involving 641 adult patients compared Viread with another medicine, adefovir dipivoxil.
Croatian: Za liječenje hepatitisa B, u dvama ispitivanjima u kojima je sudjelovala 641 odrasla osoba lijek Viread uspoređen je s drugim lijekom, tj. adefovirdipivoksilom.
English: A study in 97 children (aged 2 to 12 years) treated with stavudine or zidovudine, compared the effects of switching their treatment to Viread with continuing previous treatment.
Croatian: U ispitivanju provedenom na 97 djece (u dobi od 2 do 12 godina) liječene stavudinom ili zidovudinom uspoređeni su učinci prelaska na lijek Viread u odnosu na nastavak prethodne terapije.
English: What benefits of Viread have been shown in studies?
Croatian: Koje su koristi od lijeka Viread utvrđene u ispitivanjima?
English: 89% of patients taking Viread had a viral load below 400 copies/ml after 96 weeks of treatment, compared with 86% of patients taking the combination treatment of Viread and emtricitabine.
Croatian: U 89 % bolesnika koji su primali lijek Viread virusno opterećenje bilo je manje od 400 kopija/ml nakon 96 tjedana terapije, u usporedbi s 86 % bolesnika koji su primali kombiniranu terapiju lijeka Viread i emtricitabina.
English: In a third study involving 112 adults whose liver had stopped working properly (decompensated liver disease) Viread was compared with entecavir and a combination treatment of Viread and emtricitabine.
Croatian: U trećem ispitivanju u kojem je sudjelovalo 112 odraslih osoba u kojih je jetra prestala ispravno funkcionirati (dekompenzirana bolest jetre) lijek Viread uspoređen je s entecavirom i kombiniranom terapijom koja je obuhvaćala Viread i emtricitabin.